PhorMed
Private Company
Funding information not available
Overview
PhorMed is a private, pre-revenue biotech developing RP-323, a novel cell repair therapy targeting inflammation across oncology, neurology, and pulmonology. The company is preparing for multiple Phase 2 trials in ARDS, Parkinson's, AML, and HL, supported by recent partnerships and an equity crowdfunding campaign. Led by CEO Ben Chang and scientific founder Professor Richard L. Chang, PhorMed's strategy hinges on securing funding to advance its clinical programs and validate its platform.
Technology Platform
RP-323, a targeted cell repair immunotherapy platform that modulates inflammatory pathways to promote the body's innate repair mechanisms. It has shown preclinical activity in reducing lung and brain inflammation by targeting multiple markers, including Aquaporin 3.
Opportunities
Risk Factors
Competitive Landscape
PhorMed faces intense competition across all fronts. In ARDS, it competes with numerous biotechs exploring anti-inflammatory agents. In Parkinson's, it enters a crowded field of neuroinflammation targets pursued by major pharma. In AML and HL, it must differentiate from established chemotherapies, targeted agents, and immunotherapies. Its broad-platform approach is a differentiator but also spreads resources thin.